Description: Prescription drug markets are undergoing rapid change - significant policy changes implemented through the Inflation Reduction Act, Congressional interest in long-awaited 340b reform, and a growing direct-to-consumer market have already changed the landscape significantly. The ongoing effects of these changes will continue to evolve for many years. Hear from leading prescription drug actuaries and pharmacy policy experts on what these changes mean for prescription drug markets and US healthcare more broadly.

Description: How are regulation and innovation intertwined? How do we regulate AI/ML in the insurance industry? We will cover how regulators are striking the balance between protection of their constituents and supporting innovation. We will zoom into the case of Predictive Analytics and the regulatory attempt at avoiding undue discrimination. Let's discuss what this really means.

Description: Explore a general overview of the Medicare Advantage VBID hospice model, including program goal and a brief review of available information on plan participation in 2021 and 2022. Join us to learn how the program can support other elements related to health equity and address social determinants of health. You will be able to focus on how to improve quality of life and care using palliative, concurrent and/or transitional care and hospice services. Elevate your understanding with a summary of publicly available hospice experience data published by CMS, as well as a review of published research by the SOA and others related to hospice and end of life care. Finally, expect technical guidance regarding VBID model financial implications and proposed enhancements to the program as CMS transitions from the current model due to expire at end of 2024.

Description: Join us for an analysis of the impact of climate change on financial institution solvency, profitability, and how other key performance metrics are, or likely will be, required by financial regulators in most major economies in the very near future. Regulators are signaling that such impacts should be assessed through the use of scenario analysis, both qualitatively and quantitatively. Explore an overview of the emerging regulatory landscape for insurers as it relates to the disclosure of climate risk. After that, check out the mechanics and current best practices that actuaries and risk modelers may use in performing qualitative and quantitative climate risk scenario analyses, covering both physical and transition risks.